id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S10176 R37270 |
Blotière (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 | Craniosynostosis | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
5.86 [0.12;295.59] C excluded (control group) |
0/512 0/2,997 | 0 | 512 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9766 R34920 |
Blotière (Carbamazepine) (Controls unexposed NOS) (Mixed indications), 2019 | Craniosynostosis | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 2.39 [0.15;38.32] C | 0/512 766/1,875,733 | 766 | 512 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9612 R34097 |
D'Souza (Carbamazepine) (Controls unexposed, disease free), 1991 | Cranyosynostosis (saggital suture) | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
24.60 [0.40;1512.72] C excluded (control group) |
0/3 0/62 | 0 | 3 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9613 R34126 |
D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 | Cranyosynostosis (saggital suture) | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 3.00 [0.05;194.76] C | 0/3 0/8 | 0 | 3 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 2 studies | 2.56 [0.25;25.83] | 766 | 515 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine) (Controls unexposed NOS) (Mixed indications; 2: Carbamazepine) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 9612, 10176